September 11, 2023 7 min read Source/Disclosures Published by: Disclosures: Caranfa and Shi report no relevant financial disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> […]
The prevalence of Nasopharyngeal Cancer is increasing globally due to environmental, pathogen-mediated, and genetic factors as well as lifestyle factors, which is projected to expand the scope of the Nasopharyngeal Cancer market. Furthermore, the rising demand for effective treatment options and the increasing investments by the government and private sector to improve healthcare infrastructure are […]
Marisol Miranda-Galvis, DDS, MS, PhD A systematic review of several observational studies showed that there are 5 social determinants of health that are primarily driving survival disparities in patients with hematologic malignancies. These factors include lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status. Key […]
Ravand Samaeekia, MD, MS The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, according to data from a review presented at the 2023 SOHO Annual Meeting. Findings from the review showed that among the 40 patients treated with brentuximab vedotin plus […]
Cells | Image Credit: abhijith3747 – www.stock.adobe.com In the phase 1/2 EPCORE NHL-1 trial (NCT03625037), treatment with subcutaneous epcoritamab-bysp (Epkinly) achieved deep and durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL). Further, patients who were complete responses had favorable long-term outcomes, according to updated data presented during the 2023 SOHO Annual […]
To promote awareness and early detection, here are five types of blood cancer that you should be aware of in 2023: September marks Blood Cancer Awareness Month, a crucial time to shed light on a group of diseases that affect the blood, bone marrow, and lymphatic system. Blood cancers can have a significant impact on […]
Abstract Evidence on the impact of chemotherapy on radiotherapy-induced second malignant neoplasms is controversial. We estimated how cisplatin modulates the in vitro response of two normal cell types to fractionated radiation. AHH-1 lymphoblasts and VH10 fibroblasts were irradiated at 1 Gy/fraction 5 and 3 times per week during 12 and 19 days, respectively, and simultaneously treated with […]
Yasmin H. Karimi, MD Subcutaneous epcoritamab-bysp (Epkinly) produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial (NCT03625037) presented during the 2023 SOHO Annual Meeting.1 At a median follow-up of 20 […]
Loretta J. Nastoupil, MD, an associate professor, director of the Lymphoma Outcomes Database, and the section chief of New Drug Development in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial (NCT04245839) evaluating lisocabtagene […]
